Healthcare
Chinese cosmetic surgery app raises $50m Series D1 round
Hong Kong-listed photo editing and social networking app Meitu and a fund-of-funds managed by Shenzhen-based DH Fund have committed $50 million in Series D1 funding to Gengmei, a Chinese information platform that focuses on cosmetic surgery.
TPG to buy Healthscope's Asia pathology assets for $206m
TPG Capital has agreed to acquire the Asia pathology assets of Australian hospital operator Healthscope for A$279 million ($206 million), giving it control of 39 pathology laboratories across Singapore, Malaysia, and Vietnam.
TPG invests in India's Sai, Tata Capital exits
TPG Capital has acquired a significant minority stake in Indian drug developer and manufacturer Sai Life Sciences, providing a full exit for Tata Capital Growth Fund.
Fund focus: LPs queue up for a piece of Long Hill
China’s Long Hill Capital scales up with its latest VC fund with strong support from new and existing LPs. Sector specialization has helped underpin much of the progress
CICC leads $102m Series B for China's Allcure Medical
Beijing Allcure Medical Technology, a healthcare technology provider specializing in radiotherapy and tumor diagnosis, has received RMB700 million ($103 million) in Series B funding led by China International Capital Corp. (CICC).
Long Hill closes second China VC fund at $265m
China-focused Long Hill Capital has reached a final close of $265 million on its second US dollar-denominated VC fund as well as a first close of about $30 million for its first renminbi vehicle.
China biotech: Finding the formula
An eruption of investment and company creation in Chinese biotech has signaled the dawn of a raw but promising market. First-movers must negotiate immediate pitfalls while targeting long-term upside
China's Ascentage Pharma gets $150m in Series C funding
Ascentage Pharma, a Chinese biopharmaceutical company primarily focused on treatments for cancer, has raised $150 million in Series C funding.
LeapFrog acquires Indian medical device maker
LeapFrog Investments has acquired a majority stake in India-base healthcare industry supplier Ascent Meditech for an undisclosed sum.
Thailand's Lakeshore buys local drug brand
Lakeshore Capital has taken a controlling stake in domestic drug manufacturer Devakam Apothecary Hall, owner of the Namman Muay analgesic cream brand, for an undisclosed amount.
India's Fortis rejects TPG-backed buyout bid
Indian healthcare service provider Fortis Healthcare (FHL) has chosen IHH Healthcare as the buyer for its hospital operation, ending a protracted bidding process and rejecting a INR32 billion ($472 million) offer from TPG Capital and its portfolio company...
2Q analysis: Flipping out
Flipkart sets the tone as strategics deliver tech trade sale exits; Chinese internet players and healthcare are the trendsetters in investment; buyouts, venture stand out in Asia fundraising
Long Hill raises $252m for China VC fund, has yet to close
Long Hill Capital, a Chinese venture capital firm that spun out from New Enterprise Associates (NEA) in 2016, has raised $252.2 million for its second VC fund.
Temasek to invest $50m in TPG's Asia healthcare platform
Asia Healthcare Holdings (AHH), a healthcare-focused operating and investment platform managed by TPG Growth, has raised $50 million from Singapore’s Temasek Holdings.
China's Yunfeng buys German pharma player
China’s Yungfeng Capital has teamed up with Shenzhen-based Hybio Pharmaceutical to acquire diversified German biopharmaceuticals company AMW for an undisclosed sum.
C-Bridge hits $400m first close on China healthcare fund
C-Bridge Capital has reached a first close of just over $400 million on its third healthcare fund, which focuses on Chinese pharmaceutical, medical technology and healthcare services companies with proven products and technologies.
Vivo, Advantech invest $87m in Sinovac as take-private is abandoned
Vivo Capital and Advantech Capital have committed $86.73 million to Chinese biopharmaceutical player Sinovac Biotech. Both investors were members of a consortium that was bidding to privatize the US-listed company, but that process has been terminated.
Cancer drug developer Innovent Biologics files for HK IPO
Innovent Biologics, a Chinese drug developer company with a number of PE backers, has filed for an IPO in Hong Kong under recently introduced rules allowing listings by biotech companies with no revenue or profits.
YuanMing, Matrix lead $50m round for China's Adlai Nortye
YuanMing Capital and Matrix Partners China have led a Series B round of more than $50 million – denominated in US dollars and renminbi – for Adlai Nortye, a Chinese biopharmaceutical company.
General Atlantic invests $130m in Indian hospital operator
General Atlantic has committed $130 million to Krishna Institute of Medical Sciences (KIMS), a South India-based hospital chain that has been approved for an IPO. The company is also backed by ICICI Venture.
C-Bridge leads $20m round for China's Nuance
C-Bridge Capital, a Chinese healthcare-focused private equity firm, has led a $20 million Series B funding round for domestic pharmaceuticals developer Nuance Biotech.
Accel, IDG lead $19m round for India's SigTuple
Accel Partners and IDG Ventures have led a $19 million Series B round for Indian healthcare-focused artificial intelligence (AI) start-up SigTuple.
Profile: OneVentures' Michelle Deaker
OneVentures co-founder Michelle Deaker leveraged a background of IT innovation to introduce a much-needed dose of entrepreneurialism into the early days of Australia’s venture capital industry
China Renaissance targets $800m in Hong Kong offering
China Renaissance Holdings has filed for an IPO in Hong Kong that will support the expansion of its investment banking, investment management, and wealth management businesses. AVCJ understands the firm is planning to raise $800 million at a valuation...